

May 27, 2014



Trevena CEO to Present at the Jefferies 2014 Global Healthcare Conference

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 11:00 a.m. EDT in New York City.

To access the live audio webcast of the presentation, please visit the "Investors" section of the Company's website at www.trevenainc.com. Following the conclusion of the presentation, the webcast will be archived for 30 days.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated biased ligand product candidates into the clinic – TRV027 to treat acute heart failure, TRV130 to treat moderate-to-severe acute pain intravenously, and TRV734 to treat moderate-to-severe acute and chronic pain orally. Trevena also is advancing additional product candidates in its portfolio, including a preclinical program focused on central nervous system indications.

Investor:

Trevena, Inc.

Jonathan Violin, 610-354-8840 x231

Director of investor relations

jviolin@trevenainc.com

or

Argot Partners

Andrea Rabney, 212-600-1902

President and chief executive officer

andrea@argotpartners.com

or

Media:

Argot Partners

Eliza Schleifstein, 917-763-8106

eliza@argotpartners.com

Source: Trevena, Inc.